Clinical trials: Minimal Disease, Residual
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ipilimumab and how well it works in treating patients with high-risk myelodysplastic syndrome or acute myeloid leukemia that has come back or no longer responds to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT01757639
- Testing
- Ipilimumab, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Medulloblastoma, Childhood
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is…
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
- Trial name
- PNOC044 (NCT07346157)
- Testing
- Liothyronine (L-T3), Bevacizumab, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sabine Mueller, MD, PhD
Acute Lymphocytic Leukemia
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
A single-center, single-arm, open-label, interventional, phase II clinical trial to evaluate the efficacy and safety of InO in B-ALL achieved CR/CRi after 1L induction chemotherapy with positive minimal residual disease.
- Trial name
- NCT05456698
- Testing
- Inotuzumab ozogamicin
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Carcinoma, Hepatocellular
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC
Early stage HCC is treated by curative surgical resection or by local ablation (such as radio-frequency) as the current standard of care.
- Trial name
- NCT03020342
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Mantle Cell Lymphoma
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell transplantation.
- Trial name
- NCT03054883
- Volunteers
- 73 people
- Sponsor
- Czech Lymphoma Study Group
Multiple Myeloma
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed…
- Trial name
- NCT06483100
- Testing
- Elrantamab, clonoSEQ
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to…
- Conditions
- Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03326921
- Testing
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Small Cell Lung Cancer
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
This investigator-initiated study aims to evaluate the effectiveness of minimal residual disease (MRD) as a biomarker for guiding adjuvant therapy decisions in patients with Stage I non-small-cell lung cancer (NSCLC).
- Trial name
- MOTION-NSCLC (NCT06709274)
- Testing
- Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- 15 sites in China
- Volunteers
- 342 people
- Sponsor
- Guangdong Association of Clinical Trials
Multiple Myeloma, Cancer
Discontinuation Study
An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have…
- Conditions
- Multiple Myeloma, Cancer, Hematologic Cancer
- Trial name
- NCT05866757
- Testing
- Discontinuation of maintenance treatment
- Where
- Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Multiple Myeloma
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple myeloma (MM).
- Trial name
- NCT06302699
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
- Trial name
- LAL2317 (NCT03367299)
- Testing
- Chemotherapy + Blinatumomab
- Where
- 62 sites in Italy
- Volunteers
- 149 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03096782
- Testing
- Anti-Thymocyte Globulin, Busulfan, Clofarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Neoplastic Pathology, Minimal Residual Disease
Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues
Cryopreservation of ovarian tissue is offered to young girls and women aged under 35 who have to undergo sterilizing gonadotoxic treatment, with the aim of preserving their fertility.
- Conditions
- Neoplastic Pathology, Minimal Residual Disease, Cryopreserved Ovarian Tissue
- Trial name
- VMRDO (NCT02900625)
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
RGL-305+ Lymphoma + Exploratory Clinical Study
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma.
- Trial name
- NCT07006012
- Testing
- RGL-305
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Gastrointestinal Stromal Tumors
A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy
The goal of this single-center, prospective, observational cohort study is to learn whether tumor-informed minimal residual disease (MRD) testing in blood can predict recurrence in 66 patients with high-risk gastrointestinal…
- Trial name
- NCT05867901
- Testing
- Tumor-Informed ctDNA-Based MRD Testing, Contrast-Enhanced CT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia
New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing damage and death by inhibiting…
- Trial name
- NCT03249636
- Testing
- Flow cytometric analysis
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and…
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event
- Trial name
- ACALLO (NCT04716075)
- Testing
- Acalabrutinib 2x100 MG Oral Capsule + alloSCT
- Where
- 6 sites in Poland
- Volunteers
- 29 people
- Sponsor
- Polish Lymphoma Research Group
Acute Myeloid Leukemia
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.
- Trial name
- NCT04209712
- Testing
- haploid allogeneic NK cell therapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China